These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25945734)

  • 21. KITENIN functions as a fine regulator of ErbB4 expression level in colorectal cancer via protection of ErbB4 from E3-ligase Nrdp1-mediated degradation.
    Sun EG; Lee KH; Ko YS; Choi HJ; Yang JI; Lee JH; Chung IJ; Paek YW; Kim H; Bae JA; Kim KK
    Mol Carcinog; 2017 Mar; 56(3):1068-1081. PubMed ID: 27648936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
    Agus DB; Akita RW; Fox WD; Lewis GD; Higgins B; Pisacane PI; Lofgren JA; Tindell C; Evans DP; Maiese K; Scher HI; Sliwkowski MX
    Cancer Cell; 2002 Aug; 2(2):127-37. PubMed ID: 12204533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanisms of erbB2-mediated breast cancer chemoresistance.
    Tan M; Yu D
    Adv Exp Med Biol; 2007; 608():119-29. PubMed ID: 17993237
    [No Abstract]   [Full Text] [Related]  

  • 24. Intraductal trastuzumab treatment may be effective in the management of ductal carcinoma in situ of the breast with HER-2 overexpression.
    Altundag K; Tezcan ME; Ozen M; Karaahmet F; Bulut N
    Med Hypotheses; 2007; 68(1):235. PubMed ID: 16905272
    [No Abstract]   [Full Text] [Related]  

  • 25. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
    Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
    Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.
    Williams EE; Trout LJ; Gallo RM; Pitfield SE; Bryant I; Penington DJ; Riese DJ
    Cancer Lett; 2003 Mar; 192(1):67-74. PubMed ID: 12637154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells.
    Bae JA; Yoon S; Park SY; Lee JH; Hwang JE; Kim H; Seo YW; Cha YJ; Hong SP; Kim H; Chung IJ; Kim KK
    Clin Cancer Res; 2014 Aug; 20(15):4115-28. PubMed ID: 24893630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
    Breast Cancer Res Treat; 2015 Oct; 153(3):493-505. PubMed ID: 26400847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [miR-520a regulates ErbB4 expression and suppresses proliferation and invasion of esophageal squamous cell carcinoma].
    Ye W; Yao Q; Zhang M; Wen Q; Wang J
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):164-8. PubMed ID: 24589589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family.
    Larsen SS; Egeblad M; Jäättelä M; Lykkesfeldt AE
    Breast Cancer Res Treat; 1999 Nov; 58(1):41-56. PubMed ID: 10634517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer.
    Li Y; Zhou Z; Alimandi M; Chen C
    Oncogene; 2009 Aug; 28(33):2948-58. PubMed ID: 19561640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to Anti-HER2 Therapies in Breast Cancer.
    Rimawi MF; De Angelis C; Schiff R
    Am Soc Clin Oncol Educ Book; 2015; ():e157-64. PubMed ID: 25993167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HER2 inhibition: from discovery to clinical practice.
    Chang JC
    Clin Cancer Res; 2007 Jan; 13(1):1-3. PubMed ID: 17200331
    [No Abstract]   [Full Text] [Related]  

  • 35. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
    Yang C; Liu Y; Lemmon MA; Kazanietz MG
    Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
    Berns K; Horlings HM; Hennessy BT; Madiredjo M; Hijmans EM; Beelen K; Linn SC; Gonzalez-Angulo AM; Stemke-Hale K; Hauptmann M; Beijersbergen RL; Mills GB; van de Vijver MJ; Bernards R
    Cancer Cell; 2007 Oct; 12(4):395-402. PubMed ID: 17936563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer.
    Kurozumi S; Yamaguchi Y; Matsumoto H; Inoue K; Kurosumi M; Oyama T; Horiguchi J; Fujii T; Shirabe K
    Med Mol Morphol; 2019 Jun; 52(2):90-98. PubMed ID: 30259117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
    Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
    BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.